148 related articles for article (PubMed ID: 31337300)
1. Magnetic Resonance Imaging Findings Related to Stroke Risk in Japanese Patients With Fabry Disease.
Yagita Y; Sakai N; Miwa K; Ohara N; Tanaka M; Sakaguchi M; Kitagawa K; Mochizuki H
Stroke; 2019 Sep; 50(9):2571-2573. PubMed ID: 31337300
[TBL] [Abstract][Full Text] [Related]
2. Effect of Enzyme Replacement Therapy on Basilar Artery Diameter in Male Patients With Fabry Disease.
Miwa K; Yagita Y; Sakaguchi M; Kitagawa K; Sakai N; Mochizuki H
Stroke; 2019 Apr; 50(4):1010-1012. PubMed ID: 30852964
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
5. Brain MR Imaging Findings of Cardiac-Type Fabry Disease with an IVS4+919G>A Mutation.
Lee HJ; Hung SC; Hsu TR; Ko SC; Chui-Mei T; Huang CC; Niu DM; Lin CP
AJNR Am J Neuroradiol; 2016 Jun; 37(6):1044-9. PubMed ID: 26869469
[TBL] [Abstract][Full Text] [Related]
6. How relevant are cerebral white matter lesions in the D313Y variant of the α-galactosidase A gene? Neurological, cardiological, laboratory, and MRI data of 21 patients within a follow-up of 3 years.
Strunk D; Becker J; Veltkamp R; Meuth SG; Bauer P; Böttcher T; Rolfs A; Schwitalla JC; Kraemer M
Neurol Sci; 2023 Apr; 44(4):1375-1381. PubMed ID: 36456878
[TBL] [Abstract][Full Text] [Related]
7. Basilar artery diameter as neuroimaging biomarker in Chinese Fabry disease patients.
Lam YLT; Sheng B; Kwok HM; Yu ELM; Ma KFJ
Orphanet J Rare Dis; 2023 Jul; 18(1):186. PubMed ID: 37430370
[TBL] [Abstract][Full Text] [Related]
8. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
9. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy.
Jardim L; Vedolin L; Schwartz IV; Burin MG; Cecchin C; Kalakun L; Matte U; Aesse F; Pitta-Pinheiro C; Marconato J; Giugliani R
J Inherit Metab Dis; 2004; 27(2):229-40. PubMed ID: 15159654
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
Furujo M; Kubo T; Kobayashi M; Ohashi T
Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
[TBL] [Abstract][Full Text] [Related]
11. Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.
Barba-Romero MÁ; Pintos-Morell G
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27886142
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of Neurological Symptoms in Adult Japanese Patients with Fabry Disease.
Sawada J; Nakagawa N; Kano K; Saito T; Katayama T; Sawada T; Momosaki K; Nakamura K; Hasebe N
Intern Med; 2021 Jun; 60(12):1819-1826. PubMed ID: 33456042
[TBL] [Abstract][Full Text] [Related]
13. Brain magnetic resonance imaging findings fail to suspect Fabry disease in young patients with an acute cerebrovascular event.
Fazekas F; Enzinger C; Schmidt R; Grittner U; Giese AK; Hennerici MG; Huber R; Jungehulsing GJ; Kaps M; Kessler C; Martus P; Putaala J; Ropele S; Tanislav C; Tatlisumak T; Thijs V; von Sarnowski B; Norrving B; Rolfs A;
Stroke; 2015 Jun; 46(6):1548-53. PubMed ID: 25899239
[TBL] [Abstract][Full Text] [Related]
14. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.
Imbriaco M; Pisani A; Spinelli L; Cuocolo A; Messalli G; Capuano E; Marmo M; Liuzzi R; Visciano B; Cianciaruso B; Salvatore M
Heart; 2009 Jul; 95(13):1103-7. PubMed ID: 19372091
[TBL] [Abstract][Full Text] [Related]
15. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
16. Determinants of cerebral radiological progression in Fabry disease.
Körver S; Longo MGF; Lima MR; Hollak CEM; El Sayed M; van Schaik IN; Vedolin L; Dijkgraaf MGW; Langeveld M
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):756-763. PubMed ID: 32317398
[TBL] [Abstract][Full Text] [Related]
17. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
18. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up.
Jardim LB; Aesse F; Vedolin LM; Pitta-Pinheiro C; Marconato J; Burin MG; Cecchin C; Netto CB; Matte US; Pereira F; Kalakun L; Giugliani R
Arq Neuropsiquiatr; 2006 Sep; 64(3B):711-7. PubMed ID: 17057872
[TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease.
Stefaniak JD; Parkes LM; Parry-Jones AR; Potter GM; Vail A; Jovanovic A; Smith CJ
Neurology; 2018 Oct; 91(15):e1413-e1422. PubMed ID: 30209238
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.
Zamorano J; Serra V; Pérez de Isla L; Feltes G; Calli A; Barbado FJ; Torras J; Hernandez S; Herrera J; Herrero JA; Pintos G
Eur J Echocardiogr; 2011 Sep; 12(9):671-7. PubMed ID: 21810826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
